| Group A | Group B | Group C |
---|---|---|---|
Number of neutropenic episodes | N = 81 | N = 46 | N = 42 |
No individual patients | 66 | 41 | 38 |
Age (IQR5) | 57 (49–64) | 56 (38–64) | 59 (50–65) |
Sex female (%) | 34 (42%) | 14 (30%) | 24 (57%) |
Hematological disorder: | Â | Â | Â |
 AML (%) | 36 (44%) | 17 (37%) | 23 (55%) |
 CML (%) | 3 (4%) | 1 (2%) | 2 (5%) |
 ALL (%) | 8 (10%) | 8 (17%) | 1 (2%) |
 CLL (%) | 3 (4%) | 3 (7%) | 0 |
 HL (%) | 2 (2%) | 0 | 2 (5%) |
 NHL (%) | 11 (14%) | 7 (15%) | 4 (10%) |
 MM (%) | 14 (17%) | 9 (18%) | 7 (17%) |
 Other (%) | 4 (5%) | 2 (4%) | 3 (7%) |
Treatment type: | Â | Â | Â |
 Chemotherapy (%) | - | 29 (63%) | 29 (69%) |
 AutoSCT (%) | - | 11 (24%) | 12 (29%) |
 AlloSCT r.i. (%) | - | 2 (4%) | 1 (2%) |
 AlloSCT m.a. (%) | - | 4 (9%) | 1 (2%) |
T cell reducing medicine (%) | - | 3 (6%) | 3 (7%) |
Explicit Mucositis (%) | - | 24 (52%) | 25 (60%) |
Duration of neutropenia at sampling (IQR5) | - | 6 (5–8) | 8 (3–12) |
COPD (%) | 1 (1%) | 1 (2%) | 0 |
Smoking (%) | 7 (9%) | 4 (9%) | 3 (7%) |
URTSa (%) | 15/716 (21%) | 6 (13%) | 9 (24%) |
LRTSb | 0 | 0 | 1 (2%) |
Pulmonary aberration’s on imagery (%) | - | 2 (4%) | 10/32c (31%) |
Probable Aspergillosis (%) | - | 0 | 3 (7%) |
Positive Blood cultures (%) | - | - | 12d (29%) |